Rigel Pharmaceuticals Inc expected to post a loss of 3 cents a share - Earnings Preview

Rigel Pharmaceuticals

01/03/2024 22:05

* Rigel Pharmaceuticals Inc  RIGL.OQ   RIGL.O  is expected
to show
a fall in quarterly revenue when it reports  results on March 5
for the period ending December 31 2023
    * The South San Francisco California-based  company is
expected to
report a 33.5% decrease in revenue to $34.102 million from
$51.28 million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.The company's guidance on January 8
2024, for the period ended December 31, was for revenue of
$35.700 million.
    * ​LSEG's mean analyst estimate for Rigel Pharmaceuticals
Inc is
for a loss of 3 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rigel
Pharmaceuticals Inc is $2.00​, above​ its last closing price
of $1.52. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.07       -0.07      -0.03     Beat    57.7
 Jun. 30 2023  -0.08       -0.08      -0.04     Beat    48.7
 Mar. 31 2023  -0.09       -0.10      -0.08     Beat    17.9​
 Dec. 31 2022  -0.11       -0.11      0.01      Beat    108.9
 ​​Sep.        -0.13       -0.13      -0.11     Beat    18.2
 30 2022                                                
 Jun. 30 2022  -0.13       -0.12      -0.08     Beat    34.8​
 Mar. 31 2022  -0.14       -0.14      -0.16     Missed  -16.5
 Dec. 31 2021  -0.13       -0.13      -0.13     Met     -1.8
 This summary was machine generated March 1 at 22:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)